Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big p...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。